Neuroone Medical Technologies Corp
NASDAQ:NMTC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Neuroone Medical Technologies Corp
NeuroOne Medical Technologies Corp. operates as a medical technology company. The company is headquartered in Eden Prairie, Minnesota and currently employs 11 full-time employees. The company went IPO on 2012-11-09. The firm is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company also investigating the applications of its technology associated with artificial intelligence. The company develops its cortical, sheet and depth electrode technology to provides solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation and ablation. Its commercialized product, Evo sEEG electrode technology records, monitors and stimulates electrical signals at the subsurface level of the brain.
NeuroOne Medical Technologies Corp. operates as a medical technology company. The company is headquartered in Eden Prairie, Minnesota and currently employs 11 full-time employees. The company went IPO on 2012-11-09. The firm is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company also investigating the applications of its technology associated with artificial intelligence. The company develops its cortical, sheet and depth electrode technology to provides solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation and ablation. Its commercialized product, Evo sEEG electrode technology records, monitors and stimulates electrical signals at the subsurface level of the brain.
Record Revenue Growth: NeuroOne posted record product sales of $9.1 million for fiscal 2025, up 163% year-over-year, and $2.7 million in Q4, up 907% from the prior year quarter.
Profitability Improvement: Product gross margins grew to 56.5% for the full year and 55.8% in Q4, with operating expenses reduced by 2% in Q4 despite rapid growth.
Strategic Milestones: Achieved FDA 510(k) clearance for the OneRF trigeminal nerve ablation system and signed an expanded distribution agreement with Zimmer Biomet, also generating $3 million in license revenue.
Pipeline Expansion: Advanced new programs for drug delivery and lower back pain, including initial preclinical device sales to a large pharmaceutical company and progress toward FDA clearance for additional indications.
Reduced Losses, Stronger Balance Sheet: Net loss in fiscal 2025 improved by 71% to $3.6 million, and the company raised $8.2 million, ending the year with $6.6 million in cash and no debt.
Guidance Pending: Financial guidance for fiscal 2026 will be provided after receiving a final forecast from Zimmer Biomet.
NASDAQ Compliance: Received a 180-day extension to regain compliance with NASDAQ’s minimum bid price rule, with monitoring ongoing.
